DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03371862

SLIPS

WithdrawnPhase 2

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

—

actual

Study population

Gastrointestinal (gastroparesis / short bowel / pancreatitis)

Key I/E criterion

•BMI ≥19.5

Primary endpoint

•Improvement in parenteral support

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03371862
Org study ID17IC3834

Timeline

Milestones

Study start2017-10-20actual
Study first posted2017-12-13actual
Primary completion2020-08-06actual
Last update posted2020-08-14actual
Study completion2020-09-30estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Gastrointestinal (gastroparesis / short bowel / pancreatitis)

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

1. Short bowel (≤200cm) as a result of major intestinal resection (e.g. due to injury, volvulus, vascular disease, Crohn's disease).

2. Jejunostomy patients only

3. 12 continuous months of parenteral support (PS) dependency prior to enrolment.

4. PS required at least 3 times per week to meet their caloric, fluid or electrolyte needs due to on-going malabsorption.

5. Stable PS for at least 4 consecutive weeks immediately prior to first dose of liraglutide. Stability is described as:

1. Actual PS usage should match prescribed PS;

2. Baseline 48-hour urine output is 1-2 L/24 hours.

6. Body mass index ≥ 19.5 kg/m2.

7. Adequate hepatic and renal function:

1. Total bilirubin within the normal range;

2. Alanine aminotransferase (ALT) ≤ 2.5x upper limit of normal;

3. Serum creatinine ≤1.5x upper limit of normal.

8. Stable dosage for > 4 weeks, prior to baseline evaluations, of anti-motility and anti-diarrhoeal agents, H2 antagonists, proton pump inhibitors, bile sequestering agents and oral rehydration solutions.

9. Female subjects must be on acceptable method of contraception for a minimum of 4 weeks prior to the start of the trial; Acceptable methods of contraception would be a barrier form of contraception, oral contraceptive pill, contraceptive injection or implant or intrauterine implanted device.

Exclusion criteria

•Patients < 18 years of age
•Pregnancy (Female subjects who are not surgically sterile or post menopausal (defined as aged 55 years or older and/or at least 2 years have elapsed since the last menses) or who are not using medically acceptable methods of birth control during and for 30 days after the treatment period. Acceptable methods of contraception would be a barrier form of contraception, oral contraceptive pill, contraceptive injection or implant or intrauterine implanted device.
•Active malignancy
•Previous malignancy within the past 5 years
•History of multiple endocrine neoplasia type 2 (MEN 2)
•Personal history or family history of medullary thyroid cancer
•Raised serum calcitonin (a biomarker for medullary thyroid cancer) at beginning of trial period
•History of cardiac failure
•Concurrent use of diuretics
•Previous history of pancreatitis
•Recent use of other incretin based therapy in the previous 3 months
•Concurrent use of octreotide
•Type 1 or Type 2 diabetes
•Alcohol or drug abuse in last year
•> 4 hospitalisations related to short bowel or its treatment over the previous year
•Any hospitalisation 30 days prior to screening
•Introduction or dose adjustment of immunosuppressant for inflammatory bowel disease within 6 months, or treatment with biologics within the past 6 months (systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, MMF, infliximab, adalimumab, vedolizumab)
•BMI < 19 kg/m2 or > 27kg/m2 (An upper cut-off BMI of > 27kg/m2 has been chosen, as in these patients, there is often a desire to reduce BMI which will conflict with the study design by adding another variable)
•Scleroderma/radiation enteritis/coeliacs disease/refractory or tropical sprue
•Liver and renal function outside the inclusion range

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
2
Other (unclassified)
2
Patient-reported / QoL
1

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Improvement in quality of life

Time frame:20 weeks post start of drug

EQ-5D index

change from baseline, improvement

Other clinical outcomes

2 endpoints
Primary/protocol endpoint/low confidence

Improvement in parenteral support

Time frame:20 weeks post start of drug

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Days/Nights not requiring PS

Time frame:20 weeks

event count, improvement

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Duration of response

Time frame:20 weeks

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Change in plasma citrulline, GLP-1, IGF-1 and PYY concentrations

Time frame:20 weeks

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.